A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol

• Drug: Atorvastatin
  
  In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
• Drug: Atorvastatin
  
  In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.

• Experimental: Previous Treatment with a Usual Maintenance Dose of a Statin
  
  Intervention: Drug: Atorvastatin
• Experimental: Statin-Naive
  
  Intervention: Drug: Atorvastatin

Inclusion Criteria:

• Dyslipidemia
• At a high risk for coronary heart disease

Exclusion Criteria:

• Use of higher than usual maintenance doses of statin drugs at screening
• Uncontrolled diabetes or high blood pressure
• Impaired liver function